Amneal Targets Limited US Ciprodex Pool With FDA Approval
FDA Approval Marks Another Addition To The Firm’s Growing Complex Drug Portfolio
Executive Summary
The FDA has granted approval to Amneal’s ciprofloxacin/dexamethasone otic suspension ANDA product, referencing Ciprodex, adding a further drug to the company’s portfolio as the firm continues its strategic shift to complex generics.